Medicines Brought to Market*
MDs or PhDs on the Team
Phase 3 Success Rate**
WHAT WE DO
We partner with pharmaceutical, biotech and medical technology companies to fund products that address unmet medical needs and have the potential to improve the quality of life for patients around the world.
Filling a Void
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While the life sciences are seeing unprecedented innovation driven by rapid advancements in science and technology, there is a lack of funding necessary to bring medicines and healthcare technologies to market. We invest in and partner with pharmaceutical, biotechnology and medical technology companies to help meet this need.
Expertise and Scale
BXLS combines clinical, commercial and operational expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise.
We seek to deliver value for investors by focusing on areas where we can apply our deep clinical and commercial domain expertise. By investing in promising candidates in late-stage development, we aim to make a positive impact on the most people with the lowest clinical risk.
The Blackstone Life Sciences team of employees, Senior Advisors and Development Company personnel is responsible — both in its current capacity and prior experiences— for bringing 147 medicines to market in 17 different therapeutic areas.*
In March 2022, Blackstone Life Sciences announced a partnership with Sanofi to advance the development of Sarclisa®, a promising treatment for patients with multiple myeloma (MM), a type of blood cancer. The partnership will focus on developing a subcutaneous form of the treatment to make its delivery more convenient for patients with MM. This partnership showcases the flexible capital and deep expertise that enables BXLS to partner with leading pharmaceutical companies to advance potentially lifesaving products.
In April 2020, BXLS led a $2 billion strategic collaboration with Alnylam anchored around the acquisition of a royalty interest in inclisiran, an innovative product, which will potentially bring new benefits to patients with high cholesterol — a major risk factor for cardiovascular disease. The drug began receiving regulatory approvals globally in the fall of 2021.
Anthos Therapeutics, Inc.
In February 2019, BXLS invested in Anthos Therapeutics, Inc., in partnership with Novartis, to advance next-generation targeted therapies for high-risk cardiovascular patients. This investment will potentially help meet a large, unmet need for next-generation antithrombotic therapies for patients that are underserved by more conventional medicines. According to the American Heart Association, thrombotic disorders cause nearly 500,000 deaths each year.
Note: All figures as of December 31, 2023, unless otherwise indicated.
*Medicines brought to market by BXLS and development company employees and advisors (Nick Galakatos, Paris Panayiotopoulos, Kurt Wheeler, Barry Gertz, Dennis Henner, Ed Scolnick, Kiran Reddy, Francois Nader, Peter Honig, Elaine Caughey, Olivier Brandicourt, John Maraganore) while they worked at BXLS, Clarus and at prior employers. The development of a medicine involves many professionals. The degree of involvement by a given BXLS, advisor, or development company professional varies medicine to medicine. Therefore, the performance shown reflects the contributions of a number of professionals and may not be indicative of any individual’s contributions to the transactions. The number of developed medicines is measured when a drug is approved in any jurisdiction.
**As of January 2024. In deriving the Phase III success rate, Blackstone uses the same methodology as Evaluate Pharma. In determining the success rate, both Blackstone and Evaluate Pharma consider a drug’s approval by the US FDA or the EMA to each count as a separate, independent approval and a drug’s approval in each new indication to also be considered an approval when calculating the success rate. This methodology will result in a higher success rate than would otherwise result if only one of the aforementioned types of approval were used when calculating the success rate. For purposes of calculating the success rate, Blackstone does not include any Phase III trials that were never initiated. A trial is considered “initiated” when the first patient is enrolled in a clinical trial. For the avoidance of doubt, Blackstone considers suspended, abandoned, or never completed trials as “failures” when determining the success rate. We would be happy to provide the Clarus success rates under different time frames upon request.
Updates from Life Sciences
Blackstone Life Sciences’ Nicholas Galakatos Hails ‘New Era in Medicine’
Nick Galakatos, Global Head of Blackstone Life Sciences, discusses the recent wave of potential medicines thanks to innovation and breakthroughs in technology – and how partners like BXLS can help accelerate treatment development pipelines that would otherwise be limited by the availability of capital.
Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug
BioSpace covers Blackstone’s partnership with Sanofi, which aims to accelerate the pharma company’s ability to provide the subcutaneous formulation of multiple myeloma drug Sarclisa to patients in a more innovative and convenient manner. This investment exemplifies BXLS’ commitment to providing flexible capital to help advance vital medicines.
How Private Capital Can Yield “Healthy” Returns
The life sciences industry faces severe funding gaps that stand in the way of delivering life-saving medicines and technologies to patients. Blackstone’s expertise and capital can help address this need.
“We support promising companies and products, providing flexible capital and clinical expertise to advance innovation and improve outcomes for patients.”NICK GALAKATOS, PHD
GLOBAL HEAD OF LIFE SCIENCES